149 related articles for article (PubMed ID: 20110450)
1. Screening panels for detection of monoclonal gammopathies: confidence intervals.
Pretorius CJ; Ungerer JP; Wilgen U; Klingberg S
Clin Chem; 2010 Apr; 56(4):677-9; author reply 679-80. PubMed ID: 20110450
[No Abstract] [Full Text] [Related]
2. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic accuracy of serum protein electrophoresis and free light chain measurements for monoclonal gammopathies].
Peña C; Ortiz M; Voisin J; Peralta A; Balboa V; Delgado F
Rev Med Chil; 2018 Jan; 146(1):64-67. PubMed ID: 29806679
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of free light chain measurement in monoclonal gammopathy, other haematological malignancies and autoimmune diseases].
Verebi C; Talbot A; Gendron N; Hurtado-Nedelec M
Ann Biol Clin (Paris); 2019 Aug; 77(4):397-406. PubMed ID: 31418701
[TBL] [Abstract][Full Text] [Related]
7. [Current role of the laboratory in the demonstration and follow up of monoclonal immunoglobulinopathy].
Myara I
Pathol Biol (Paris); 1990 Feb; 38(2):134-43. PubMed ID: 2107510
[TBL] [Abstract][Full Text] [Related]
8. Free light-chains and renal disorders: when small is worse.
Stratta P; Airoldi A; Izzo C; Rossi D; Gaidano GL
Lancet; 2010 Oct; 376(9748):1221; author reply 1221-2. PubMed ID: 20934589
[No Abstract] [Full Text] [Related]
9. Should routine laboratories stop doing screening serum protein electrophoresis and replace it with screening immune-fixation electrophoresis? No quick fixes: Counterpoint.
Smith JD; Raines G; Schneider HG
Clin Chem Lab Med; 2016 Jun; 54(6):967-71. PubMed ID: 26677889
[TBL] [Abstract][Full Text] [Related]
10. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
[TBL] [Abstract][Full Text] [Related]
11. Screening immunofixation should replace protein electrophoresis as the initial investigation of monoclonal gammopathy: Point.
Pretorius CJ
Clin Chem Lab Med; 2016 Jun; 54(6):963-6. PubMed ID: 26574893
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.
Wood PB; McElroy YG; Stone MJ
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):278-80. PubMed ID: 20709664
[TBL] [Abstract][Full Text] [Related]
13. [Detection of free light chains--a new method of diagnostics of haematological diseases].
Mecl J; Benáková H; Nohejlová A; Straub J; Zima T; Spicka I
Cas Lek Cesk; 2007; 146(2):159-62. PubMed ID: 17373113
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathy of undetermined significance: an update for nephrologists.
Parry HM; Pratt G; Hutchison CA
Adv Chronic Kidney Dis; 2012 Sep; 19(5):291-6. PubMed ID: 22920639
[TBL] [Abstract][Full Text] [Related]
15. Comparison of capillary zone and immunosubtraction with agarose gel and immunofixation electrophoresis for detecting and identifying monoclonal gammopathies.
Litwin CM; Anderson SK; Philipps G; Martins TB; Jaskowski TD; Hill HR
Am J Clin Pathol; 1999 Sep; 112(3):411-7. PubMed ID: 10478148
[TBL] [Abstract][Full Text] [Related]
16. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
17. Utility of immunofluorescence of urine sediment for identifying patients with renal disease due to monoclonal gammopathies.
Fogazzi GB; Pozzi C; Passerini P; Simonini P; Locatelli F; Ponticelli C
Am J Kidney Dis; 1991 Feb; 17(2):211-7. PubMed ID: 1899532
[TBL] [Abstract][Full Text] [Related]
18. [Sixth International Symposium on clinical applications of serum free light chain analysis, Bath, England, 23-24 September 2010].
Decaux O
Rev Med Interne; 2011 Jan; 32(1):64-6. PubMed ID: 21126805
[No Abstract] [Full Text] [Related]
19. The monoclonal gammopathies.
Kyle RA
Clin Chem; 1994 Nov; 40(11 Pt 2):2154-61. PubMed ID: 7955402
[TBL] [Abstract][Full Text] [Related]
20. Laboratory testing in monoclonal gammopathy of renal significance (MGRS).
Leung N; Barnidge DR; Hutchison CA
Clin Chem Lab Med; 2016 Jun; 54(6):929-37. PubMed ID: 27107835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
